Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
2022 · Frontiers in Oncology · 7 citations
https://doi.org/10.3389/fonc.2022.843032
D
Donghua He
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
1.0K
Citations
16
h-index
22
i10-index
Donghua He is an academic researcher from Shanghai University. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Peptidase Inhibition and Analysis & Protein Degradation and Inhibitors. The author has an h-index of 16, co-authored 96 publications.
ORCID: 0000-0002-9268-8732Papers by this author
worksThe Clinical Characteristics and Prognosis of Chinese Patients with Light-Chain Amyloidosis: A Retrospective Multicenter Analysis
2021 · Indian Journal of Hematology and Blood Transfusion · 5 citations
https://doi.org/10.1007/s12288-021-01469-y
Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia
2025 · European journal of medical research · 5 citations
https://doi.org/10.1186/s40001-025-02637-w
P-394 Selinexor Combined With Bortezomib, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Who Have Undergone Severe Treatment: A Single-Arm, Multicenter, Prospective Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)02296-1
P-166 Characteristics of Immune-Genes Rearrangements in Chinese Multiple Myeloma Patients
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)02069-x
Efficacy and Safety of Low-frequency Daratumumab in Systemic Light-chain Amyloidosis
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)04018-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat